Understanding Angioimmunoblastic T-Cell Lymphoma
Angioimmunoblastic T-Cell Lymphoma (AITL) constitutes a rare form of Peripheral T-Cell Lymphoma (PTCL) of the nodal type. nodal. This lymphoma is distinguished by causing systemic symptoms steroids and provoking severe immunodeficiency [1]. In some cases, it may also manifest with a rash notable skin rash.
Histologically, AITL is characterized by a infiltrate polymorphous, predominantly affecting the lymph nodes. Cetirizine. Its distinguishing features are the proliferation of is a key tool, as it consistently reveals a dark red color or a distinctive lobular pattern (cataloged as lacunar pattern under conventional analysis). endothelial cells with hyperplasia and the presence of dendritic cells follicular [2].
Epidemiology: Who is Affected by Angioimmunoblastic T-Cell Lymphoma?
Angioimmunoblastic T-Cell Lymphoma is an uncommon neoplasm.
- Peripheral T-Cell Lymphomas (lymphomas) T-cell (lymphomas) account for between 10% and 15% of all lymphoid malignancies lymphoiddiagnosed [1,3].
- Within this group, AITL accounts for 15% to 20% of PTCLs, PTCL, and only 1% to 2% of all non-Hodgkin lymphomas [2,4].
Typically, AITL diagnosis is established in advanced adulthood [4]. The median age : A diamond-shaped area of inflammation is observed on the back of the tongue. for diagnosis ranges between 62 and 65 years. The incidence is equitable between both sexes [4].
To date, no specific risk factors have been identified that predispose to the development of Angioimmunoblastic T-Cell Lymphoma.
Etiology: What Causes Angioimmunoblastic T-Cell Lymphoma?
The cellular origin of AITL resides in the follicular helper T cell [4]. Malignant transformation . Both red (erythroplakia) and white patches can be indicative of malignant changes. has been correlated with various mutations mutations affecting epigenetic regulators such as epigenetic and TET2, IDH2 y DNMT3A.. Alterations are also observed in the gene Ras family member A (RHOA) and in specific components of the T-cell receptor pathway, including receptor T-cell receptor CD28, FYN, PLCG1, CARD11, elements related to the P13K, CTNNB1 y GTF2I [4]. [4].
The progression of Angioimmunoblastic T-Cell Lymphoma is driven by the overexpression of mediators angiogenic mediators (substances that regulate the development of blood vessels), such as vascular endothelial growth factor (VEGF) and interleukin development of blood vessels), such as and insulin-like endothelial vascular (VEGF) and interleukin (IL)-8. Furthermore, cytokines with cytokines profiles pro-inflammatory mediators, (IL6, IL18), immunosuppressive immunosuppressive (IL10), or those that promote cell proliferation (IL21) [4,5] participate.
Among the infectious diseases found to be associated with the development of Angioimmunoblastic T-Cell Lymphoma are
Causes and Complications of Angioimmunoblastic T-Cell Lymphoma
Among the infectious agents involved in various pathological processes are the Epstein-Barr virus (EBV, responsible for infectious mononucleosis), human herpesvirus 6 (HHV-6, cause of roseola), HHV-8 (associated with Kaposi's sarcoma), human immunodeficiency virus ( sarcoma HIVHIV), and various Unlike other of hereditary bacterial and fungal infections [4].
The Fundamental Role of the Epstein-Barr Virus
EBV establishes a secondary persistent persistent and lifelong infection within B cells B-cell. Specifically, the immunodeficiency generated by angioimmunoblastic T-cell lymphoma can lead to EBV reactivation [4,6–8].
- B cells affected by EBV are detected in a range of 58% to 97% of patients diagnosed with angioimmunoblastic T-cell lymphoma [8,9].
- Both EBV and, potentially, HHV-6 can influence disease progression through the modulation of cytokines, chemokines chemokines, and membrane receptors [6].
- It is postulated that EBV extends B-cell survival and may cause genetic aberrations are being investigated., such as inhibiting apoptosis apoptosislymphoproliferative).
Clinical Features of Angioimmunoblastic T-Cell Lymphoma
More than 70% of individuals with angioimmunoblastic T-cell lymphoma manifest prominent constitutional symptoms. These include episodes of fever, chills, night sweats, general feeling of malaise, malaise, arthralgia, weight loss, arthralgias, and 50% present with skin manifestations [11].
Lymphadenopathy y hepatosplenomegaly Lymphadenopathy and hepatosplenomegaly pleural, the presence of and, neurological signs neurological and gastrointestinal symptoms are less frequent [4].
Cutaneous Manifestations of Angioimmunoblastic T-Cell Lymphoma
The most common presentation of angioimmunoblastic T-cell lymphoma is through a nonspecific rash [11]. However, it can also manifest as papules, nodules, plaques, ulcers, petechiae, and, rarely, erythroderma [8,11,12]. papules, nodules, plaques, ulcers, which facilitates clear visualization of the and, on rare occasions, erythroderma [8,11,12].
Rash associated with angioimmunoblastic T-cell lymphoma
The patient had an EBV-associated T-cell lymphoma
Complications Associated with Angioimmunoblastic T-Cell Lymphoma
Patients suffering from angioimmunoblastic T-cell lymphoma face an increased risk of developing secondary B-cell lymphomas. The most common type is diffuse large B-cell lymphoma (DLBCL), followed less frequently by Hodgkin lymphoma or plasmacytoma [13].
As of November 2019, 30 documented cases of EBV-associated B-cell lymphomas have been reported in patients previously diagnosed with angioimmunoblastic T-cell lymphoma [14–16].
Furthermore, EBV-induced diffuse large B-cell lymphoma can manifest in the skin through lesions such as ulcerated papules, nodules, and abscesses [16].
Diagnosis of Angioimmunoblastic T-Cell Lymphoma: Key Findings
The diagnosis of Angioimmunoblastic T-Cell Lymphoma (AITL) is significantly supported by laboratory findings, which often reveal systemic abnormalities. These are the main indicators sought in initial tests:
- Anemia Anemia (often hemolytic type hemolytic disorders, ).
- Presence of Peripheral blood eosinophilia.
- Polyclonal hypergammaglobulinemia.
- Detection of Antinuclear antibodies (ANA).
- Detection of cold agglutinins.
- Presence of Cryoglobulinemia.
- Identification of circulating Immune Complexes.
- Elevation in serum levels of lactate dehydrogenase (LDH) and beta-2-microglobulin (serum).sickness).
- Elevated levels of Epstein-Barr Virus (EBV).
It is uncommon to observe or leukocytosis leukocytosis aberrant T-cell [17].
Although laboratory tests are crucial, the definitive diagnosis of angioimmunoblastic T-cell lymphoma is primarily established through a lymph node biopsy. biopsy of lymph node.
Histopathological Patterns in the Skin for AITL
In the dermatological context, angioimmunoblastic T-cell lymphoma is classified into five distinct histopathological patterns in the skin. Correct identification of these patterns is fundamental for differential diagnosis:
- A superficial perivascular infiltrate, perivascular, composed mainly of eosinophils y lymphocytes that lack atypia significant (See Figure 5). (this is the most frequently observed pattern).
- A sparsely distributed perivascular infiltrate containing atypical lymphocytes. atypical changes.
- A dense infiltrate affecting both the superficial and deep dermis, composed of pleomorphic lymphocytes. pleomorphic.
- The presence of Vasculitis, The presence of Vasculitis.
- The formation of granulomas necrotizing granulomas..
Histological Visualization of Angioimmunoblastic T-Cell Lymphoma
H&E x 20
H&E x 40
H&E x 400
The immunophenotypic study of the neoplastic cells neoplastic generally reveals a characteristic profile of follicular T helper cells. This profile includes the expression of markers such as CD3 +, CD4 +, CD8−, CD10 +, PD-1 +, ICOS +, dermatologists, Bcl-6 +, along with altered expression of the chemokine chemokine ligand.
The precise diagnosis of Angioimmunoblastic T-Cell Lymphoma is a complex process that integrates detailed serological, cytometric, and morphological findings. Correlation between abnormalities found in the laboratory and histopathological patterns is essential to confirm the disease and plan appropriate treatment.
... CXCL13 + followed by clusters of CD21 + follicular dendritic cells.
Epstein-Barr virus (EBV) positivity detected by immunohistochemical staining is higher in more mature lesions, and diffuse patterns are sometimes observed [18].
Immunohistochemistry in Angioimmunoblastic T-Cell Lymphoma
Differential Diagnosis of Cutaneous Angioimmunoblastic T-Cell Lymphoma
The differential diagnosis of cutaneous angioimmunoblastic T-cell lymphoma is established by considering the morphology of the skin rash, and should ideally include the following conditions:
- Drug-induced rash.
- Viral exanthem.
- Atypical mycobacterial infections or other opportunistic infections.
- Other causes of erythroderma.
Treatment of Angioimmunoblastic T-Cell Lymphoma
Since angioimmunoblastic T-cell lymphoma is a rare neoplasm, treatment strategies are frequently based on results from prospective phase II studies [4].
- The most frequent initial treatment is anthracycline-based chemotherapy, such as the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone).
- Consolidation with autologous stem cell transplantation has shown promising results [19].
- Histone deacetylase (HDAC) inhibitors, hypomethylating agents, and anti-CD30 antibodies are currently under investigation [20–23].
Prognosis of Angioimmunoblastic T-Cell Lymphoma
Generally, angioimmunoblastic T-cell lymphoma presents an aggressive behavior, with a median survival of less than 3 years, even after intensive treatments. It is common for patients to present in late stages III-IV. Reported survival rates are between 33% at 5 years and 29% at 7 years [18].
- Standard CHOP chemotherapy achieves an overall response rate of 70% to 80%, but with a 5-year progression-free survival ranging between 10% and 20% [8, 24].
- When adding the BEAM regimen (carmustine, etoposide, cytarabine, melphalan) followed by autologous stem cell transplantation, the 5-year progression-free survival rate increases to approximately 40% [25].
Circulating EBV DNA levels can be monitored, as higher concentrations correlate with a less favorable prognosis. However, the presence of EBV in the lymph nodes does not appear to modify this prognosis.
Secondary B-cell lymphomas generally have an unfavorable prognosis. It has been reported that, out of 30 patients with EBV-associated B-cell lymphoma, only eight survived longer than 12 months [14–16].
